Merck Serono research brings a balance of small molecules, proteins and monoclonal antibodies into the early clinical development pipeline. A broad base of technological expertise allows us to exploit the full potential of the biological and chemical spheres. The application of new technologies and a broader platform of therapeutic molecules, enhanced by combined experience, is a key factor for innovation.
Our integrated drug discovery process allows a disease-oriented approach, selecting the therapeutic method best suited to treat that disease. Our objective is to bring the best compound to the clinic by a clear Proof-of-Concept strategic approach in order to obtain a confirmed mode of action on patients.
Our research strategy is also supported by strong portfolio and business development from the discovery phase. Our network of alliances with other biotech companies and academic groups fosters a constant flow of innovations into the organisation by enriching our disease knowledge and technological capabilities.